Xenetic Biosciences, Inc. - 8-K Filing
Xenetic Biosciences reported first-quarter 2026 financial results with royalty revenue of $0.8 million, up 36% YoY; R&D expenses were $0.7 million (down 25%), and net loss was $0.5 million (49% lower than the prior year). The company ended Q1 with $7.3 million in cash while advancing its DNase oncology platform through translational research, manufacturing readiness, and investigator-initiated studies. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $XBIO